<li>abiraterone<p>dexamethasone decreases levels of abiraterone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Avoid coadministration of abiraterone with strong CYP3A4 inducers; if a strong CYP3A4 inducer must be used, increase abiraterone dosage frequency from once daily to twice daily.</p></li><li>aceclofenac<p>aceclofenac, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>acemetacin<p>acemetacin, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>albiglutide<p>dexamethasone decreases effects of albiglutide by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully. .</p></li><li>alitretinoin<p>dexamethasone will decrease the level or effect of alitretinoin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>almotriptan<p>dexamethasone will decrease the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>alprazolam<p>dexamethasone will decrease the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>amiodarone<p>dexamethasone will decrease the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>amiodarone will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>antithrombin alfa<p>dexamethasone, antithrombin alfa. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>antithrombin iii<p>dexamethasone, antithrombin iii. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>aprepitant<p>aprepitant will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>argatroban<p>dexamethasone, argatroban. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>aripiprazole<p>dexamethasone will decrease the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>armodafinil<p>armodafinil will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>artemether/lumefantrine<p>artemether/lumefantrine will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>aspirin<p>aspirin, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>aspirin rectal<p>aspirin rectal, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>atazanavir<p>atazanavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>atorvastatin<p>dexamethasone will decrease the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>atorvastatin will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>atracurium<p>atracurium, dexamethasone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>avanafil<p>dexamethasone will decrease the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. For patients with ED, monitor response carefully because of potential for decreased effectiveness.</p></li><li>bazedoxifene/conjugated estrogens<p>dexamethasone will decrease the level or effect of bazedoxifene/conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>belatacept<p>belatacept and dexamethasone both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor.</p></li><li>bemiparin<p>dexamethasone, bemiparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>bexarotene<p>dexamethasone will decrease the level or effect of bexarotene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bivalirudin<p>dexamethasone, bivalirudin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>bortezomib<p>dexamethasone will decrease the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosentan<p>bosentan will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>bosutinib<p>bosutinib increases levels of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>brentuximab vedotin<p>dexamethasone decreases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>brexpiprazole<p>dexamethasone will decrease the level or effect of brexpiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Double brexpiprazole dose over 1-2 weeks if administered with a strong CYP3A4 inducer.</p></li><li>budesonide<p>budesonide will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>buprenorphine<p>dexamethasone will decrease the level or effect of buprenorphine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>buprenorphine buccal<p>dexamethasone will decrease the level or effect of buprenorphine buccal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>buprenorphine subdermal implant<p>dexamethasone will decrease the level or effect of buprenorphine subdermal implant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inducer for signs and symptoms of withdrawal. If the dose of the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, implant removal may be necessary and the patient should then be treated with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inducer is discontinued in a patient who has been stabilized on buprenorphine, monitor the patient for overmedication.</p></li><li>buspirone<p>dexamethasone will decrease the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>butalbital<p>butalbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>calcifediol<p>dexamethasone, calcifediol. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Drugs that stimulate microsomal hydroxylation reduce the half-life of calcifediol.</p></li><li>carbamazepine<p>dexamethasone will decrease the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>celecoxib<p>celecoxib, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>cholera vaccine<p>dexamethasone decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine.</p></li><li>cholestyramine<p>cholestyramine decreases levels of dexamethasone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>cilostazol<p>dexamethasone will decrease the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>cimetidine<p>dexamethasone will decrease the level or effect of cimetidine by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>cinacalcet<p>dexamethasone will decrease the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ciprofloxacin<p>dexamethasone and ciprofloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>cisatracurium<p>cisatracurium, dexamethasone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>clarithromycin<p>clarithromycin will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clobetasone<p>clobetasone will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>clopidogrel<p>dexamethasone will increase the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inducers may increase the metabolism of clopidogrel to its active metabolite. Monitor patients for potential increase in antiplatelet effects when CYP3A4 inducers are used in combination with clopidogrel</p></li><li>clotrimazole<p>clotrimazole will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>clozapine<p>dexamethasone will decrease the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>colchicine<p>dexamethasone will decrease the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conivaptan<p>conivaptan will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conjugated estrogens<p>dexamethasone will decrease the level or effect of conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>conjugated estrogens, vaginal<p>dexamethasone will decrease the level or effect of conjugated estrogens, vaginal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>corticorelin<p>dexamethasone decreases effects of corticorelin by unspecified interaction mechanism. Use Caution/Monitor. ACTH response to corticorelin may be blunted with pretreatment with dexamethasone.</p></li><li>cortisone<p>cortisone will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>crizotinib<p>dexamethasone decreases levels of crizotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Concomitant use of strong CYP3A inducers should be avoided.  .<span><br><br></span>crizotinib increases levels of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.<span><br><br></span>crizotinib increases levels of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>crofelemer<p>crofelemer increases levels of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed.</p></li><li>cyclosporine<p>cyclosporine will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>cyclosporine will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dabrafenib<p>dabrafenib will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>daclatasvir<p>daclatasvir will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dalteparin<p>dexamethasone, dalteparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>darifenacin<p>darifenacin will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>darunavir<p>darunavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dasatinib<p>dasatinib will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>deferasirox<p>deferasirox will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>delavirdine<p>delavirdine will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>denosumab<p>dexamethasone, denosumab. Other (see comment). Use Caution/Monitor. 
Comment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections.</p></li><li>dhea, herbal<p>dhea, herbal will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>diazepam<p>dexamethasone will decrease the level or effect of diazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dichlorphenamide<p>dichlorphenamide and dexamethasone both decrease  serum potassium. Use Caution/Monitor.</p></li><li>diclofenac<p>diclofenac, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>diflunisal<p>diflunisal, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>diltiazem will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>doxorubicin<p>dexamethasone will decrease the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>doxorubicin liposomal<p>dexamethasone will decrease the level or effect of doxorubicin liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>dronabinol<p>dexamethasone will decrease the level or effect of dronabinol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dronabinol is a CYP3A4 substrate.</p></li><li>dronedarone<p>dronedarone will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dronedarone will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>dyphylline<p>dexamethasone will decrease the level or effect of dyphylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>efavirenz<p>efavirenz will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eletriptan<p>dexamethasone will decrease the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eliglustat<p>eliglustat increases levels of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.</p></li><li>elvitegravir/cobicistat/emtricitabine/tenofovir df<p>elvitegravir/cobicistat/emtricitabine/tenofovir df increases levels of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP3A4 inhibitor; contraindicated with CYP3A4 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.</p></li><li>enoxaparin<p>dexamethasone, enoxaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>erlotinib<p>dexamethasone will decrease the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>erythromycin base<p>erythromycin base will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin ethylsuccinate<p>erythromycin ethylsuccinate will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin lactobionate<p>erythromycin lactobionate will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>erythromycin stearate<p>erythromycin stearate will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>eslicarbazepine acetate<p>eslicarbazepine acetate will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estradiol<p>dexamethasone will decrease the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estrogens conjugated synthetic<p>dexamethasone will decrease the level or effect of estrogens conjugated synthetic by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estrogens esterified<p>dexamethasone will decrease the level or effect of estrogens esterified by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>estropipate<p>dexamethasone will decrease the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ethotoin<p>ethotoin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>ethotoin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>etodolac<p>etodolac, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>etoposide<p>dexamethasone will decrease the level or effect of etoposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>etoricoxib<p>etoricoxib, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>etravirine<p>dexamethasone will decrease the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>etravirine will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>eucalyptus<p>eucalyptus will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>exemestane<p>dexamethasone will decrease the level or effect of exemestane by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>exenatide injectable solution<p>dexamethasone decreases effects of exenatide injectable solution by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully. .</p></li><li>exenatide injectable suspension<p>dexamethasone decreases effects of exenatide injectable suspension by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully.</p></li><li>felodipine<p>dexamethasone will decrease the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>felodipine will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>fenbufen<p>fenbufen, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fenoprofen<p>fenoprofen, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fentanyl<p>dexamethasone will decrease the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects.</p></li><li>fentanyl intranasal<p>dexamethasone will decrease the level or effect of fentanyl intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects.</p></li><li>fentanyl iontophoretic transdermal system<p>dexamethasone will decrease the level or effect of fentanyl iontophoretic transdermal system by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects.</p></li><li>fentanyl transdermal<p>dexamethasone will decrease the level or effect of fentanyl transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects.</p></li><li>fentanyl transmucosal<p>dexamethasone will decrease the level or effect of fentanyl transmucosal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with CYP3A4 inducers could lead to a decrease in fentanyl plasma concentrations, lack of efficacy or, possibly, development of a withdrawal syndrome in a patient who has developed physical dependence to fentanyl. After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase which could increase or prolong both the therapeutic and adverse effects.</p></li><li>fesoterodine<p>dexamethasone will decrease the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fingolimod<p>dexamethasone increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. .</p></li><li>flibanserin<p>dexamethasone will decrease the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inducers substantially decrease flibanserin systemic exposure.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fludrocortisone<p>dexamethasone will decrease the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>flurbiprofen<p>flurbiprofen, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>fondaparinux<p>dexamethasone, fondaparinux. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>fosamprenavir<p>fosamprenavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>fosphenytoin<p>fosphenytoin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>fosphenytoin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>gefitinib<p>dexamethasone will decrease the level or effect of gefitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase gefitinib to 500 mg daily if coadministered with a strong CYP3A4 inducer.  Resume gefitinib dose at 250 mg/day 7 days after discontinuing the strong inducer.</p></li><li>gemifloxacin<p>dexamethasone and gemifloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>glycerol phenylbutyrate<p>dexamethasone decreases effects of glycerol phenylbutyrate by Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may cause the breakdown of body protein and increase plasma ammonia levels; monitor ammonia levels closely when glycerol phenylbutyrate is coadministered with corticosteroids.</p></li><li>grapefruit<p>grapefruit will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>griseofulvin<p>griseofulvin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>guanfacine<p>dexamethasone will decrease the level or effect of guanfacine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong or moderate CYP3A4 inducers significantly reduce guanfacine plasma concentrations and elimination half-life. If coadministered, more frequent dosing of the IR product may be required to achieve or maintain the desired hypotensive response. For patients with ADHD, FDA-approved labeling for ER guanfacine recommends that, if coadministered, doubling the recommended dose of guanfacine should be considered.</p></li><li>hemin<p>dexamethasone decreases effects of hemin by pharmacodynamic antagonism. Use Caution/Monitor. Drugs that increase delta-aminolevulinic acid synthetase may decrease hemin effect.</p></li><li>heparin<p>dexamethasone, heparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hydrocortisone<p>dexamethasone will decrease the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>hydroxyprogesterone caproate<p>dexamethasone will decrease the level or effect of hydroxyprogesterone caproate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ibuprofen<p>ibuprofen, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>iloperidone<p>dexamethasone will decrease the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>iloperidone increases levels of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Iloperidone is a time-dependent CYP3A inhibitor and may lead to increased plasma levels of drugs predominantly eliminated by CYP3A4.</p></li><li>indacaterol, inhaled<p>dexamethasone, indacaterol, inhaled. serum potassium. Use Caution/Monitor. Combination may increase risk of hypokalemia.</p></li><li>indinavir<p>indinavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>indinavir will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>indomethacin<p>indomethacin, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>influenza virus vaccine (h5n1)<p>dexamethasone decreases effects of influenza virus vaccine (h5n1) by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids used in greater than physiologic doses may reduce immune response to H5N1 vaccine.</p></li><li>influenza virus vaccine (h5n1), adjuvanted<p>dexamethasone decreases effects of influenza virus vaccine (h5n1), adjuvanted by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids used in greater than physiologic doses may reduce immune response to H5N1 vaccine.</p></li><li>influenza virus vaccine quadrivalent, recombinant<p>dexamethasone decreases effects of influenza virus vaccine quadrivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>influenza virus vaccine trivalent, recombinant<p>dexamethasone decreases effects of influenza virus vaccine trivalent, recombinant by pharmacodynamic antagonism. Use Caution/Monitor. Immune response to vaccine may be decreased in immunocompromised individuals.</p></li><li>insulin degludec<p>dexamethasone decreases effects of insulin degludec by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Endogneous cortisol is a regulatory hormone that increases blood glucose levels; exogenous systemic corticosteroids have been associated with hyperglycemia and may cause diabetes with chronic, high dose use; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin degludec/insulin aspart<p>dexamethasone decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Endogneous cortisol is a regulatory hormone that increases blood glucose levels; exogenous systemic corticosteroids have been associated with hyperglycemia and may cause diabetes with chronic, high dose use; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>insulin inhaled<p>dexamethasone decreases effects of insulin inhaled by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Endogneous cortisol is a regulatory hormone that increases blood glucose levels; exogenous systemic corticosteroids have been associated with hyperglycemia and may cause diabetes with chronic, high dose use; dose of antidiabetic agents may need adjustment and increased frequency of glucose monitoring may be required.</p></li><li>irinotecan<p>dexamethasone will decrease the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>irinotecan liposomal<p>dexamethasone will decrease the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>isoniazid<p>isoniazid will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ixabepilone<p>dexamethasone will decrease the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>ketoprofen<p>ketoprofen, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>ketorolac<p>ketorolac, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>ketorolac intranasal<p>ketorolac intranasal, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>lacidipine<p>dexamethasone will decrease the level or effect of lacidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>lapatinib<p>lapatinib will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of lapatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>lapatinib will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lepirudin<p>dexamethasone, lepirudin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>lercanidipine<p>dexamethasone will decrease the level or effect of lercanidipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levobupivacaine<p>dexamethasone will decrease the level or effect of levobupivacaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levofloxacin<p>dexamethasone and levofloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>levonorgestrel intrauterine<p>dexamethasone decreases levels of levonorgestrel intrauterine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>levonorgestrel oral<p>dexamethasone decreases levels of levonorgestrel oral by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>linagliptin<p>dexamethasone will decrease the level or effect of linagliptin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Use of alternative treatments is strongly recommended when linagliptin is to be administered with a P-gp inducer.</p></li><li>liraglutide<p>dexamethasone decreases effects of liraglutide by pharmacodynamic antagonism. Use Caution/Monitor. Corticosteroids may diminish hypoglycemic effect of antidiabetic agents. Monitor blood glucose levels carefully. .</p></li><li>lomitapide<p>lomitapide increases levels of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. Consider reducing dose when used concomitantly with lomitapide.</p></li><li>lopinavir<p>dexamethasone will decrease the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>loratadine<p>dexamethasone will decrease the level or effect of loratadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>loratadine will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lornoxicam<p>lornoxicam, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>lovastatin<p>lovastatin will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>lumefantrine<p>lumefantrine will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>maraviroc<p>dexamethasone will decrease the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>marijuana<p>marijuana will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>meclofenamate<p>meclofenamate, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>medroxyprogesterone<p>dexamethasone will decrease the level or effect of medroxyprogesterone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Contraceptirve failure possible. Use alternative if available.</p></li><li>mefenamic acid<p>mefenamic acid, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>meloxicam<p>meloxicam, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>meningococcal group b vaccine<p>dexamethasone decreases effects of meningococcal group b vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mestranol<p>dexamethasone will decrease the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>methadone<p>dexamethasone will decrease the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>methylprednisolone<p>dexamethasone will decrease the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>mibefradil<p>mibefradil will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>midazolam<p>dexamethasone will decrease the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>midazolam will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>mitotane<p>mitotane decreases levels of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.</p></li><li>modafinil<p>modafinil will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>moxifloxacin<p>dexamethasone and moxifloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>nabumetone<p>nabumetone, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>naproxen<p>naproxen, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>nefazodone<p>nefazodone will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nelfinavir<p>nelfinavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nevirapine<p>nevirapine will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>nicardipine<p>dexamethasone will decrease the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nicardipine will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nifedipine<p>nifedipine will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.<span><br><br></span>nifedipine will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>nilotinib will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>nisoldipine<p>dexamethasone will decrease the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>norfloxacin<p>dexamethasone and norfloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>ocrelizumab<p>dexamethasone and ocrelizumab both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Coadministration of ocrelizumab with high doses of corticosteroids is expected to increase the risk of immunosuppression.</p></li><li>ofloxacin<p>dexamethasone and ofloxacin both increase  Other (see comment). Use Caution/Monitor. Coadministration of quinolone antibiotics and corticosteroids may increase risk of tendon rupture.</p></li><li>olodaterol inhaled<p>dexamethasone and olodaterol inhaled both decrease  serum potassium. Use Caution/Monitor.</p></li><li>ombitasvir/paritaprevir/ritonavir<p>ombitasvir/paritaprevir/ritonavir will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Paritaprevir and ritonavir inhibit P-gp. Caution if coadministered with P-gp substrates.</p></li><li>ondansetron<p>dexamethasone will decrease the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No dosage adjustment for ondansetron is recommended for patients on these drugs.</p></li><li>ospemifene<p>dexamethasone decreases levels of ospemifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxaprozin<p>oxaprozin, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>oxcarbazepine<p>oxcarbazepine will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxiconazole<p>oxiconazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>oxycodone<p>dexamethasone decreases levels of oxycodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>paclitaxel<p>dexamethasone will increase the level or effect of paclitaxel by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>paclitaxel protein bound<p>dexamethasone will increase the level or effect of paclitaxel protein bound by  Other (see comment). Use Caution/Monitor. Paclitaxel levels/toxicity may increase when coadministered with CYP2C8 inhibitors </p></li><li>pancuronium<p>pancuronium, dexamethasone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>parecoxib<p>parecoxib, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>pazopanib<p>dexamethasone will decrease the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>phenindione<p>dexamethasone, phenindione. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>phenobarbital will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>phenytoin<p>phenytoin will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>phenytoin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>pimavanserin<p>dexamethasone will decrease the level or effect of pimavanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid coadministration if possible. Monitor for reduced pimavanserin efficacy. An increase in pimavanserin dosage may be needed.</p></li><li>piroxicam<p>piroxicam, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>pomalidomide<p>dexamethasone decreases levels of pomalidomide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of multiple doses of 4 mg pomalidomide with 20 mg to 40 mg dexamethasone (a weak-to-moderate inducer of CYP3A4) to patients with multiple myeloma had no effect on the pharmacokinetics of pomalidomide compared with pomalidomide administered alone. .</p></li><li>ponatinib<p>ponatinib increases levels of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>posaconazole<p>posaconazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>prednisolone<p>dexamethasone will decrease the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>prednisone<p>dexamethasone will decrease the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>primidone<p>primidone will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>protamine<p>dexamethasone, protamine. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>quercetin<p>quercetin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>quetiapine<p>dexamethasone will decrease the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quinidine<p>dexamethasone will decrease the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>quinupristin/dalfopristin<p>quinupristin/dalfopristin will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ranolazine<p>ranolazine will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>repaglinide<p>dexamethasone will decrease the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>reserpine<p>reserpine will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifampin<p>rifampin will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>rimonabant<p>dexamethasone will decrease the level or effect of rimonabant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>riociguat<p>dexamethasone will decrease the level or effect of riociguat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Data not available for dose adjustment</p></li><li>ritonavir<p>ritonavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>ritonavir will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rivaroxaban<p>dexamethasone decreases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid concomitant use of rivaroxaban with drugs that are combined P-gp and strong CYP3A4 inducers. Consider increasing the rivaroxaban dose if these drugs must be coadministered.</p></li><li>rocuronium<p>rocuronium, dexamethasone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>romidepsin<p>dexamethasone will decrease the level or effect of romidepsin by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>rufinamide<p>rufinamide will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>salicylates (non-asa)<p>salicylates (non-asa), dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>salsalate<p>salsalate, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>saquinavir<p>dexamethasone will decrease the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>simvastatin<p>simvastatin will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sipuleucel-t<p>dexamethasone decreases effects of sipuleucel-t by pharmacodynamic antagonism. Modify Therapy/Monitor Closely.</p></li><li>sirolimus<p>sirolimus will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>sodium picosulfate/magnesium oxide/anhydrous citric acid<p>dexamethasone, sodium picosulfate/magnesium oxide/anhydrous citric acid.
Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. 
Comment: May be associated with fluid and electrolyte imbalances such as hypokalemia.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate<p>dexamethasone and sodium sulfate/potassium sulfate/magnesium sulfate both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol<p>dexamethasone and sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol both decrease  serum potassium. Modify Therapy/Monitor Closely.</p></li><li>solifenacin<p>dexamethasone will decrease the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>somatrem<p>dexamethasone decreases effects of somatrem by pharmacodynamic antagonism. Use Caution/Monitor.</p></li><li>sorafenib<p>dexamethasone decreases levels of sorafenib by increasing metabolism. Use Caution/Monitor.</p></li><li>spironolactone<p>spironolactone will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>st john's wort<p>st john's wort will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>succinylcholine<p>succinylcholine, dexamethasone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>sulfasalazine<p>sulfasalazine, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>sulindac<p>sulindac, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>sunitinib<p>dexamethasone will decrease the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>suvorexant<p>dexamethasone will decrease the level or effect of suvorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inducers may decrease suvorexant efficacy; if increased suvorexant dose required, do not exceed 20 mg/day</p></li><li>tacrolimus<p>dexamethasone will decrease the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>tacrolimus will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>tadalafil<p>dexamethasone will decrease the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid combination in pulmonary HTN patients. For patients with ED, monitor response to tadalafil carefully because of potential for decreased effectiveness.</p></li><li>tamoxifen<p>dexamethasone will decrease the level or effect of tamoxifen by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tasimelteon<p>dexamethasone will decrease the level or effect of tasimelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid coadministration of tasimelteon with strong CYP3A4 inducers</p></li><li>telithromycin<p>telithromycin will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>temsirolimus<p>dexamethasone will decrease the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>theophylline<p>dexamethasone will decrease the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>ticagrelor<p>dexamethasone decreases levels of ticagrelor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid use of ticagrelor with potent CYP3A inducers.</p></li><li>tinzaparin<p>dexamethasone, tinzaparin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>tipranavir<p>dexamethasone will decrease the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tofacitinib<p>dexamethasone will decrease the level or effect of tofacitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Loss of, or decreased response to tofacitinib may occur when coadministered with potent CYP3A4 inducers</p></li><li>tolfenamic acid<p>tolfenamic acid, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>tolmetin<p>tolmetin, dexamethasone.
Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of GI ulceration.</p></li><li>tolterodine<p>dexamethasone will decrease the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>tolvaptan<p>tolvaptan will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>topiramate<p>topiramate will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>toremifene<p>dexamethasone decreases levels of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP3A4 inducers increase rate of toremifene metabolism, lowering the steady-state concentration in serum.</p></li><li>tramadol<p>dexamethasone will decrease the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Decreased AUC  of tramadol and the active metabolite (O-desmethyltramadol) when coadministered with strong CYP3A4 and CYP2B6 inducers</p></li><li>trazodone<p>dexamethasone will decrease the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>trazodone will decrease the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>triamcinolone<p>dexamethasone will decrease the level or effect of triamcinolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>triazolam<p>dexamethasone will decrease the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>troglitazone<p>troglitazone will decrease the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>troleandomycin<p>troleandomycin will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>vardenafil<p>dexamethasone will decrease the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li><li>vecuronium<p>vecuronium, dexamethasone. Other (see comment). Use Caution/Monitor. 
Comment: Coadministration of corticosteroids and neuromuscular blockers may increase risk of developing acute myopathy.</p></li><li>vemurafenib<p>vemurafenib increases levels of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>verapamil<p>verapamil will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>verapamil will increase the level or effect of dexamethasone by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor.</p></li><li>vilazodone<p>dexamethasone decreases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Consider increasing vilazodone dose up to 2-fold (not to exceed 80 mg/day) when coadministered with strong CYP3A4 inducers for &gt;14 days.</p></li><li>voriconazole<p>voriconazole will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone will decrease the level or effect of voriconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.</p></li><li>vortioxetine<p>dexamethasone decreases levels of vortioxetine by increasing metabolism. Modify Therapy/Monitor Closely. Consider increasing the vortioxetine dose when coadministered with strong CYP inducers for &gt;14 days; not to exceed 3 times original vortioxetine dose.</p></li><li>warfarin<p>dexamethasone will decrease the level or effect of warfarin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.<span><br><br></span>dexamethasone, warfarin. Other (see comment). Use Caution/Monitor. 
Comment: Corticosteroids may decrease anticoagulant effects by increasing blood coagulability; conversely, they may impair vascular integrity, thus increasing bleeding risk.  Monitor INR closely.</p></li><li>xipamide<p>xipamide, dexamethasone. pharmacodynamic synergism. Use Caution/Monitor. Risk of hypokalemia.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.</p></li>